drugset / Trial / NCT00452504

Single Ascending Dose Study of SRA-444 in Healthy Subjects

NCT00452504 ↗

Phase 1 Completed 64 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

This is a first-in-humans study of SRA-444. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SRA-444 (SR formulation) after administration of ascending single oral doses to healthy adult subjects.

Timeline

Start
2007-02
Primary completion
—
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SRA-444 Unknown — Oral

Indications